Subscribe to Search results

In a journal article in the Lancet, it was reported that "If the UK had been self-sufficient in factor concentrates, and these results had been replicated, generally they suggest that over 80% of the infections which occurred would have been spared".

Published on:

In Glasgow Royal Infirmary, the 77 patients whose blood was tested for HIV as part of a study were not told that these tests were taking place.

Published on:

Figures relating to the annual consumption of commercial factor concentrate at different haemophilia centres between 1976 and 1994. Also included are the factor types, product names, haemophilia type, number of units and volume amounts.

Published on:

At a Committee on Safety of Medicines Sub-Committee on Biological Products meeting, it was stated that the cause of AIDS was unknown. It was postulated that a new agent may have beeen responsible, but repeated exposure to, or reactivation of, known agents, (e.g. CMV, EBV) may have beeen involved.

Published on:

The UKHCDO recommended at the end of the 1983 meeting that patients did not switch from concentrates to cryo.

Published on:

Professor Franklin described in a letter how he and Professor Hill took the view that patients should have continuity in their factor product and given how erratic the NHS supply was it was better to keep them on commercial Factor VIII than switch between the two when NHS product was available.

Published on:

Dr Ala advised the West Midlands Working Party meeting - through letter - that cryoprecipitate was "probably a safer product than Factor VIII concentrate in respect of transmission of AIDS".

Published on:

The Working Party meeting did not result in any change of approach in regards to cryoprecipitate.

Published on:

The Queen Elizabeth Hospital return for 1983 showed some treatment with cryoprecipitate in hospital but predominantly treatment with NHS concentrate and Factorate in both hospital and home settings.

Published on:

The return for 1984 showed for the Queen Elizabeth Hospital that there was predominantly treatment with NHS concentrate and Factorate in both hospital and home settings.

Published on:

It was noted at Working Party meeting on the Treatment of Haemophiliacs that there was a shortfall of 3.5 million units of Factor 8 which it was agreed should be made up by commercial Factor 8.

Published on:

Professor Franklin wrote to Dr Lane registering his concern about the shortfall, which meant that the Centre might have to treat patients with commercial product who had never been exposed to it in the past.

Published on:

The West Midlands Working Party held an extraordinary meeting to discuss the implications of the use of Factor 8 concentrates in light of the death of two people with haemophilia from AIDS and a treatment policy was agreed

Published on:

Professor Bloom told the audience at a Haemophilia Society meeting that one of his patients "may have a mild form" of the syndrome.

Published on:

NETR Haemophilia Working Party agreed to use heat-treated material whenever possible and to treat all new patients and those with mild haemophilia with heat-treated NHS concentrate or small pool Factor 8 concentrate if treatment with cryoprecipitate or DDAVP was not possible.

Published on:

The Royal Free's annual return for 1983 showed that commercial concentrates remained the principal treatment for Haemophilia A.

Published on:

The Royal Free's annual return for 1984 showed that commercial concentrates remained the principal treatment for Haemophilia A, although the volume of NHS concentrates increased.

Published on:

Dr Kernoff wrote to patients explaining that it would not be possible to change everybody to heat-treated products immediately. The overall objective of the Royal Free's policy was said to be to give the safest possible treatment to an individual.

Published on:

In a letter to John Watt, it was stated that Dr Ludlam planned to start an active home therapy programme for some of his haemophilic patients.

Published on:

In his witness statement, Professor Ludlam accepted that cryoprecipitate had transformed the treatment of patients with Haemophilia A and allowed most bleeds in non-inhibitor patients to be treated effectively.

Published on: